U.S. Markets closed

InflaRx N.V. (IF0.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
2.2840-0.0160 (-0.70%)
At close: 5:35PM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close2.3000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's Range2.2660 - 2.2840
52 Week Range1.9000 - 5.7980
Avg. Volume9,293
Market Cap100.922M
Beta (5Y Monthly)0.48
PE Ratio (TTM)N/A
EPS (TTM)-1.1000
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    InflaRx to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

    JENA, Germany, Sept. 09, 2021 (GLOBE NEWSWIRE) -- InflaRx (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announces that Prof. Niels C. Riedemann, Chief Executive Officer and Founder, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually. The presentation will be available on demand starting at 7:00 AM EDT / 1:00 PM CET on Monday, Septe

  • GlobeNewswire

    InflaRx to Proceed with Pivotal Development for Vilobelimab in Hidradenitis Suppurativa with New Primary Endpoint

    InflaRx received feedback from FDA within its Type A meeting which is supportive of a new primary endpoint measuring reductions in all three inflammatory HS lesions – including reductions of draining tunnels (previously referred to as draining fistulas)InflaRx will focus its pivotal development program on patients suffering from moderate to severe HS with active draining disease, as supported by the FDAInflaRx will incorporate FDA feedback in the study protocol for its pivotal program and submit

  • Benzinga

    InflaRx's Vilobelimab Shows Encouraging Signs Of Drug Activity In Mid-Stage Study With Dermatological Ulcer Patients

    InflaRx N.V. (NASDAQ: IFRX) has announced data from the first 10 evaluable patients in the ongoing Phase 2a open-label study with vilobelimab in Pyoderma Gangraenosum (PG). PG is a rare condition that causes large, painful sores (ulcers) to develop on the skin, most often on the legs. Over a treatment period of 26 weeks (until day 189), patients were treated biweekly with vilobelimab 800mg, 1600mg, or 2400mg, after an initial run-in phase with three doses of 800mg on days 1, 4, and 8. Out of the